PATH vs TXG
Uipath Inc (PATH) versus 10X Genomics Inc (TXG) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
10X Genomics Inc (TXG) is a health information services company listed on NASDAQ.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported TXG revenue for 2024-12-31 was $610.8M. Net income was -$182.6M. Revenue was down 1.3% from 2023-12-31 to 2024-12-31. TXG currently screens at market cap $4.08B.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. TXG currently screens at market cap $4.08B.
Not investment advice. Open the PATH and TXG stock pages for the full models.
Not investment advice.